| Zugriffe | |
|---|---|
| Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study | 160 |
| Mai 2025 | Juni 2025 | Juli 2025 | August 2025 | September 2025 | Oktober 2025 | November 2025 | |
|---|---|---|---|---|---|---|---|
| Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study | 0 | 5 | 14 | 0 | 7 | 21 | 2 |
| Zugriffe | |
|---|---|
| 2020_Philipp_etal.pdf | 175 |
